Kornimate/medical-research-clean huggingface dataset:
the effect of manual therapy and exercise in patients with chronic low back pain

Conditions: Chronic Low Back Pain

Summary: identification of the effects of spinal stabilization exercises and manual therapy methods on pain, function and quality of life in individuals with low back pain.

113 patients participating in the study were divided into two groups. the patients in the physiotherapy group were instructed to perform special spinal stabilization exercises, while the patients in the manual therapy group were instructed to perform soft tissue mobilizations, muscle-energy techniques, joint mobilizations and/or manipulation methods depending on the nature of their lower back pain problems. both groups were offered stabilization, strengthening, stretching, balance and exercise trainings as well as recommendations as to the daily life activities in line with the requirements of each individual. the severity of the pain suffered by the individuals was evaluated through a visual analog scale. oswestry disability index and short form-36 (sf-36) scale were made respectively with respect to the functional condition and life quality. assessments were repeated before and after the treatment.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic low back pain * must have pain at least 3 or more according to visual analog scale exclusion criteria: * clinical diagnosis of rheumatoid arthritis * clinical diagnosis of alzheimer * clinical diagnosis of peripheral neuropathy * clinical diagnosis of diabetes mellitus
an multicentre clinical study to evaluate the usability and safety of the autoinjector and pre-filled syringe of sb4 in subjects with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: a study comparing the usability of the autoinjector and pre-filled syringe of sb4 in subjects with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * subjects are male or female aged 18-55 years at the time of signing the informed consent form. exclusion criteria: * have been treated previously with monoclonal antibody agent including any tumour necrosis factor inhibitor except sb4.
quality of life in ipf - patient and physician perceptions

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this study aims to evaluate the differences between patient's and their physicians' perception of quality of life and the effect of disease severity and co-morbidities. patients and physicians will complete two sets of questionnaires at an initial clinic visit and again six months later.

idiopathic pulmonary fibrosis is a progressive and debilitating disease characterized by progressive scarring of the lung parenchyma of unknown cause. in the us approximately 100,000 individuals have been diagnosed with this disease and the only cure available is lung transplantation. there have been two drugs approved by the fda for treatment of ipf which have demonstrated the ability to slow disease progression but have no impact on quality of life. symptoms of ipf include shortness of breath, cough, and fatigue which all contribute to a decreased quality of life. additionally, these symptoms and the need for supplemental oxygen use causes significant psychological and social impairment. multiple questionnaires have been used to measure patient reported quality of life in both clinical and research settings. the king's brief interstitial lung disease (kbild) questionnaire is a disease-specific patient reported outcome measure and has been validated across several different patient groups and countries. additionally, the euroqol group has developed the euroqol five dimensional 5-level (eq-5d-5l) questionnaire which is a non-disease specific assessment of health-related quality of life and has not yet been widely used in a population of patients with ipf. significant disparity between patient and physician perception of quality of life has been demonstrated across different disease processes. while there are many contributing factors to overall wellbeing the general assumption is that with more advanced disease quality of life predictably decreases. the investigators plan to test this hypothesis to better understand the complex relationship between chronic disease and quality of life in patients with ipf.

Eligibility criteria:
inclusion criteria: * patients with a multidisciplinary diagnosis of ipf according to the 2018 ats/ers/jrs/alat clinical practice guidelines. * all ranges of disease severity based on pulmonary function testing: forced vital capacity (fvc) and diffusing capacity (dlco). exclusion criteria: * any impairment or co-morbid disease that results in an inability to read or understand a questionnaire or provide informed consent. the study team member will make this determination according to their best clinical judgement. * the questionnaires will be administered in english language only and thus this study will be conducted in patients who are able to read, write, and speak english language.

Keywords: quality of life questionnaire
study to evaluate jcxh-211 as monotherapy in patients with malignant solid tumors

Conditions: Cutaneous Tumor; Malignant Solid Tumor

Summary: a phase 1 open-label study to evaluate the safety, tolerability and efficacy of jcxh-211 intratumoral injection in patients with malignant solid tumors

the main purpose of this study is to find out how safe and tolerable the study drug, jcxh-211, is and also how well it works in people with malignant solid tumors. the study drug jcxh-211, is an immunotherapy drug. this means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. the study has 2 main phases: phase 1a and phase 1b. phase 1a has 3 stages, single administration stage, multiple administration stage and visceral stage. phase 1b will not start until all the data collected in phase 1a has been completed and reviewed to check that it is safe and well tolerated.

Eligibility criteria:
inclusion criteria: all of the following conditions should be met at screening: * male or female patients 18-75 * patients with malignant solid tumors that have been diagnosed by pathology and/or cytology * patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist * patients with at least one non-injected measurable tumor lesion per recist v1.1 * patients with lesions suitable for intratumoral injection (the lesion length is at least 10 mm and not exceeding 80 mm) * patients enrolled in the single and multiple administration stages of phase 1a must agree to provide pre- and post-treatment tumor biopsy tissues * patients must have adequate organ and marrow functions * patients with treated brain metastases are eligible if meeting protocol's requirement * patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin c), hormonal, biological, targeted agents, other investigational therapy or radiotherapy exclusion criteria: patients who meet any of the following criteria will be excluded from study entry: * patients who have received prior il-12 either alone or as part of a treatment regimen * patients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a grade 3 or higher immune-related adverse event (irae) * patients requiring therapeutic doses of anticoagulation * patients with tumors that impinge on major airways, blood vessels, or nerve bundles * patients with a history of autoimmune disease that has the possibility of recurrence or active autoimmune disease that requires immunosuppressive medications * patients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment * current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment * patient with history of solid organ or allogenic bone marrow transplantation

Keywords: tumor intratumoral injection
symmetric vs asymmetric blr recession in management of basic ixt with ocular dominance

Conditions: Intermittent Exotropia

Summary: the study aims to investigate ocular motor and sensory outcomes of two different strategies of lateral rectus recession; symmetric and asymmetric, in management of basic type intermittent exotropia with ocular dominance.

surgical management of basic -type intermittent exotropia with a dominant eye is controversial. some surgeons do traditional symmetrical bilateral lateral rectus recession, while other perform unilateral recess-resect procedure in the non-dominant eye. the aim of this study is to investigate the effect of two different strategies of bilateral lateral rectus recession; symmetrical recession in which the amount of recession is equally divided between both eyes, and asymmetrical recession, in which the amount of recession is 2mm more in the non-dominant. outcome measures include ocular deviation at distant and near fixation, sensory status and complications.

Eligibility criteria:
inclusion criteria: * basic-type intermittent exotropia * simulated distant-type intermittent exotropia exclusion criteria: * alternating basic-type intermittent exotropia (no ocular dominance) * distant-type intermittent exotropia * convergence-insufficiency type intermittent exotropia * constant exotropia * sensory exotropia * deep amblyopia * paralytic or restrictive exotropia * previous extraocular muscle surgery
brain slice explants to predict drug response in brain tumors

Conditions: Central Nervous System Tumor

Summary: this biospecimen collection study will evaluate the feasibility of engrafting and testing resected central nervous system (cns) tumors tumor tissue ex vivo to estimate drug response, in pediatric and adult subjects. cns tumors display remarkable heterogeneity and unfortunately there are no reliable precision oncology platforms that can identify the most effective therapy for each patient. recent work has demonstrated the success of functional precision oncology platforms using patient-derived explant (pde) at predicting drug response in various cancers. since pdes maintain important aspects of tumor heterogeneity they may prove effective as functional models for cns tumors. the purpose of this study is to explore the feasibility of using a novel pde platform to generate drug sensitivity scores from patients with central nervous system tumors in pediatric and adult subjects having low- or high-grade cns tumors resected. the secondary objective is to estimate the proportion of successfully scaled pdes generated per given tumor size.


Eligibility criteria:
in order to participate in this study a subject must meet all of the eligibility criteria outlined below. inclusion criteria: 1. written informed consent obtained to participate in the study and hipaa authorization for the release of personal health information or written assent and parental consent for pediatric subjects or surrogate consent provided by the subject's legally authorized guardians. 2. a diagnosis of a tumor residing in the central nervous system with surgery plan to have surgical resection. 3. the subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designer. exclusion criteria: 1. all subjects must not meet any of the following exclusion criteria prior to enrollment to participate in this study: any serious medical or psychiatric disorder that would interfere with the subject's ability to give informed consent. 2. incarcerated individuals.

Keywords: patient-derived explant tissue
pharmacists as gate keepers in suicide prevention: needs of pharmacists

Conditions: Pharmacist-Patient Relations; Suicide; Suicide, Attempted; Suicidal Ideation

Summary: this study aims to examine the opinions and needs of pharmacists and pharmaceutical technical assistants (fta) concerning their role as gatekeepers in suicide prevention. the primary objective is to map the experiences and needs of (public) pharmacists and fta with regard to suicide prevention. the secondary objective is to be able to develop more targeted tools, interventions or trainings based on the results of the needs assessment in order to facilitate the role of (public) pharmacists and fta as gatekeepers in suicide prevention.


Eligibility criteria:
inclusion criteria: * working as a (public) pharmacist or pharmaceutical technical assistant (fta) * 18 years or older * access to a computer, tablet or mobile phone with internet access * dutch-speaking exclusion criteria: * hospital pharmacists or industrial pharmacists are not included in this study and thus constitute an exclusion criterion.
prevalence of primary aldosteronism in patients with stroke

Conditions: Primary Aldosteronism; Stroke

Summary: strokes leads to significant morbidity and mortality, and hypertension is the most important risk factor for strokes. it is estimated that up to 10% of patients with hypertension have the underlying, treatable condition of primary aldosteronism. hence, we hypothesize that the prevalence of primary aldosteronism is high in patients with strokes, a complication of long-standing hypertension. patients admitted with an acute stroke to the acute stroke unit, changi general hospital, will be screened for primary aldosteronism three months post-stroke, and confirmatory tests will be done with saline-infusion test.


Eligibility criteria:
inclusion criteria: 1. age 21-80 years 2. admitted with acute cerebrovascular accident (cva) or transient ischemic attack (tia) to the asu, cgh 3. patients with both ischemic and hemorrhagic strokes exclusion criteria: a. pregnant patients

Keywords: hypertension arrhythmia adrenal vein sampling mineralocorticoid-receptor antagonists
efficacy of pain treatment on depression in patients with dementia

Conditions: Depression; Pain; Dementia

Summary: the purpose of this study is to determine whether pain treatment can reduce symptoms of depression in patients suffering from dementia and depression. depression is commonly diagnosed in patients with dementia. if the investigators find a reduction in depressive symptoms when pain treatment is applied, this will support the hypothesis that undiagnosed pain may present itself as depression in patients with dementia.


Eligibility criteria:
inclusion criteria: * patients residing in long term nursing home units for at least 4 weeks prior to study * diagnosed with probable or possible dementia according to diagnostic and statistical manual of mental disorders (dsm-iv), fast score \> 4 * diagnosed with depression ≥ 4 week duration as measured by csdd ≥ 8 * written, informed consent provided by the participant (if they have capacity) or assent (if they do not have capacity) and a written proxy informed consent from a legally authorized representative empowered to make health-related decisions for the potential study participant exclusion criteria: * the patient is contra-indicated to study drugs of pain treatment, in another trial, or had no carer. * participants are ineligible if they are clinical critical (e.g. suicide risk) * clinician responsible for care, or study clinician considers that the patient suffers from any physical condition, which would make participation in the trial distressing or likely to increase suffering * advanced severe medical disease/disorder with expected survival less than 6 months or that could interfere with participation * psychosis or other severe mental disorder prior to dementia diagnosis * severe aggression (≥8) on item 3 of the npi subscale, with aggression as the predominant symptom * schizophrenia, schizoaffective disorder and bipolar disorder * uncontrolled epilepsy * severe liver impairment * renal failure * severe injury or anaemia (hb \< 8.5 mmol/l), comatose state, current enrolment in another experimental protocol * known allergy or adverse reaction to paracetamol or buprenorphine transdermal patch * advanced severe medical disease with expected survival of less than six months, severe psychiatric or neurological disorder. * patients with diseases that make it impossible to follow the research schedule are excluded

Keywords: pain measurement pain assessment pain management analgesia analgesics depressive symptoms alzheimer disease vascular dementia multi-infarct dementia frontotemporal lobar degeneration lewy body disease
pilates pelvic floor strengthening program to improve urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: does a twice weekly, 12-week pilates pelvic floor strengthening program improve short- and long-term measures of stress urinary incontinence symptoms in women ages 45-70 years of age?


Eligibility criteria:
inclusion criteria: 1. age 45-70 years of age. 2. able to provide informed consent. 3. able to lower and rise from the floor safely and independently. 4. anticipated to be able to attend at least 9 of the first 12 classes (75%) in weeks 1-6. 5. anticipated to be able to attend at least 9 of the final 12 classes (75%) in weeks 7-12. 6. score of 6+ on iciq-ui short form. exclusion criteria: 1. pregnancy 2. unable to speak and comprehend english 3. chronic neurologic condition (e.g., parkinson's or multiple sclerosis) that impacts bladder function.

Keywords: pelvic floor strengthening stress urinary incontinence
comparison of amblyztm glasses and patching for amblyopia

Conditions: Amblyopia

Summary: electronic eyeglasses, amblyz™glasses, are a new medical device designed to treat amblyopia, which intermittently become opaque and provide effective occlusion for 50% of the time they are worn. a non-randomized study reported that amblyz glasses yield an improvement in the amblyopic eye and offer an alternative effective treatment. we are unaware of any randomized clinical trial reports of response to amblyztm glasses treatment of amblyopia. our hypothesis: amblyz™glasses can improve visual acuity of the amblyopic eye as effective as traditional patching treatment. the primary objective is to determine if amblyztm equally treats moderate amblyopia as the standard 2-hour patching treatment and amblyztm equally treats severe amblyopia as the standard 6-hour patching treatment. this study is designed to evaluate the effectiveness of a novel amblyopia treatment, amblyztm glasses, in treating amblyopia. moderate amblyopia: children ages 3 to \<8 years with visual acuity of 20/40 to 20/80 in the amblyopic eye will be enrolled and randomized into two groups: 4-hour amblyztm glasses treatment group and standard 2-hour patching control group. severe amblyopia: children ages 3 to \<8 years with visual acuity of 20/100 to 20/400 in the amblyopic eye will be enrolled and randomized into two groups: 12-hour amblyztm glasses treatment group and standard 6-hour patching control group.


Eligibility criteria:
inclusion criteria: * both genders and all races are eligible to this study. * age 3 to 8 years * amblyopia associated with strabismus, anisometropia, or both * visual acuity in the amblyopic eye between 20/40 and 20/80 inclusive * visual acuity in the sound eye 20/40 or better and inter-eye acuity difference \>3 logarithm of the minimum angle of resolution (logmar) lines * wearing of optimal spectacle correction for a minimum of 4 weeks at the time of enrollment. exclusion criteria: • no amblyopia treatment before enrollment.

Keywords: amblyopia
mdr explor radial head system pmcf

Conditions: Elbow Injury

Summary: the objective of this retrospective and prospective consecutive series pmcf study is to collect long-term data confirming safety, performance and clinical benefits of the explor radial head system (implants and instrumentation) when used for radial head arthroplasty.

this is a global, multi-center, retrospective enrollment, prospective follow-up, consecutive series post-market clinical follow-up study. the intent of the study is that subjects who have already had the surgical implant will be retrospectively enrolled in the study and data will be collected for a minimum of 10 years post-operatively. subjects treated with the device will be identified and invited to participate in the study. 93 subjects will be enrolled into the study.

Eligibility criteria:
inclusion criteria: patient must have undergone primary elbow arthroplasty with the explor radial head system according to a cleared indication, which includes the following: * replacement of the radial head for degenerative or post-traumatic disabilities presenting pain, crepitation and decreased motion at the radio-humeral and/or proximal radio-ulnar joint with: joint destruction and/or subluxation visible on x-ray resistance to conservative treatment * primary replacement after fracture of the radial head * symptomatic sequelae after radial head resection patient must be 18 years of age or older. patient must be willing and able to follow directions. exclusion criteria: * infection * sepsis * osteomyelitis * uncooperative patient or patient with neurological disorders who are incapable of following directions * osteoporosis * metabolic disorders which may impair bone formation * osteomalacia * distant foci of infections which may spread to implant site * rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram * patient is a prisoner. * patient is a current alcohol or drug abuser. * patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent * patient is known to be pregnant or breastfeeding. * patient is unwilling to sign informed consent.